Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

BackgroundADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T-cells are genetically engineered autologous T-cells that express a high-affinity melanoma-associated antigen (MAGE)-A10-specific T-cell receptor (TCR) targeting MAGE-A10-positive tumors in the context of human leukocyte antige...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	David S. Hong, Marcus O. Butler, Russell K. Pachynski, Ryan Sullivan, Partow Kebriaei, Sarah Boross-Harmer, Armin Ghobadi, Matthew J. Frigault, Ecaterina E. Dumbrava, Amy Sauer, Francine Brophy, Jean-Marc Navenot, Svetlana Fayngerts, Zohar Wolchinsky, Robyn Broad, Dzmitry G. Batrakou, Ruoxi Wang, Luisa M. Solis, Dzifa Yawa Duose, Joseph P. Sanderson, Andrew B. Gerry, Diane Marks, Jane Bai, Elliot Norry, Paula M. Fracasso
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2022-03-01
Reeks:	Frontiers in Oncology
Onderwerpen:	HNSCC melanoma urothelial carcinoma ADP-A2M10 MAGE-A10 adoptive cellular therapy
Online toegang:	https://www.frontiersin.org/articles/10.3389/fonc.2022.818679/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!